KRYS (Krystal Biotech Inc.) stock: $336.67, $9.96B market cap, $845.6M cash, $9.12B EV, $10.63B fully diluted market cap. Next expected readout: Nov-26. Lead program: KB803 (Dystrophic Epidermolysis Bullosa), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$9,119.4M
Balance sheet
| Cash | $845.6M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $845.6M |
|---|
| Enterprise value | $9,119.4M |
|---|
| Basic shares | 29.6M shares |
|---|
| Fully diluted shares | 31.6M shares |
|---|
| Fully diluted market cap | $10,630.0M |
|---|
| Cash per share | $28.57 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading KRYS daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Dec 13, 2026 - Jan 24, 2027 | KB111 | Early Phase 1 | Hailey Hailey Disease; Skin Diseases; Lesion Skin | — |
| Jan 12 - Feb 23 | KB803 | Phase 3 | Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa | Q4 2026 |
| Jan 12 - Feb 23 | KB801 | Phase 2 | Neurotrophic Keratitis | — |
| Jan 12 - Feb 23 | KB407 (Nebulization) | Phase 1 | Cystic Fibrosis | — |
| Mar 15 - Apr 26 | KB707 | Phase 2 | Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult | — |
| Aug 12 - Sep 23 | KB707 | Phase 2 | Cancer; Melanoma Stage III; Melanoma Stage IV | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
VYJUVEK
Approved · Active Modality: redosable topical gene therapy
Aliases beremagene geperpavec-svdt, B-VEC
Target COL7A1
Indications- dystrophic epidermolysis bullosa (DEB) (Approved)
Status note First and only corrective therapy for DEB in approved markets (US, EU, UK, Japan); exclusive worldwide rights held by Krystal.
KB803
Phase 3 · Active Modality: redosable eye drop gene therapy (B-VEC formulation)
Target COL7A1
Indications- corneal abrasions in DEB (Phase 3)
- ocular complications of DEB (Phase 3)
Status note IOLITE Phase 3 registrational study enrollment completed April 2026; dosing schedule modified after initial safety observation.
KB801
Stage not disclosed · Active Modality: eye drop HSV-1 vector gene therapy
Target NGF (nerve growth factor)
Indications- neurotrophic keratitis (Stage not disclosed)
Status note EMERALD-1 protocol amended to enable it to serve as a registrational trial; FDA platform technology designation for the engineered HSV-1 vector.
KB407
Phase 1 · Active Modality: HSV-1 vector gene therapy
Target CFTR
Indications- cystic fibrosis (Phase 1)
Status note CORAL-1 Phase 1; repeat-dose study enrolling; in discussions with FDA, CFF and TDNCC on registrational pathway.
KB408
Phase 1 · Active Modality: inhaled (nebulized) HSV-1 vector gene therapy
Target SERPINA1
Indications- alpha-1 antitrypsin deficiency (AATD) lung disease (Phase 1)
Status note SERPENTINE-1 Phase 1 dose escalation; no discontinuation disclosed.
KB111
Phase 1 · Active Modality: topical gel HSV-1 vector gene therapy
Target ATP2C1
Indications- Hailey-Hailey disease (Phase 1)
Status note HALITE-1 open-label study enrolling; FDA Fast Track and platform technology designations.
KB707
Phase 1 · Active Modality: redosable immunotherapy (transcutaneous injection and inhaled formulations)
Target IL-2; IL-12
Indications- solid tumors (Phase 1)
- non-small cell lung cancer (inhaled formulation) (Phase 1)
Status note KYANITE-1 Phase 1/2 dose escalation and expansion; FDA RMAT, Fast Track and Rare Pediatric Disease designations.
KB304
Phase 1 · Active Modality: intradermal injection HSV-1 vector gene therapy
Target COL3A1 (collagen type III alpha 1); elastin
Indications- wrinkles of the decollete (aesthetics) (Phase 1)
Status note PEARL-2 Phase 1 completed; developed through Jeune Aesthetics subsidiary; no discontinuation disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.